Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study


Creative Commons License

Reinmuth N., Goldman J. W., Garassino M. C., Chen Y., Hotta K., Poltoratskiy A., ...More

ANNALS OF ONCOLOGY, vol.33, 2022 (SCI-Expanded) identifier